News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Jul 10, 2019

Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales

Glinski to Oversee US Sales for XTANDI
- Photos 1
Jun 3, 2019

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-
May 30, 2019

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -
May 20, 2019

Astellas Oncology Announces C³ Prize® Call for Entries to Award $200,000 to the Best Ideas in Cancer Care Beyond Medicine

-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply -
May 9, 2019

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary
- Photos 1
May 5, 2019

New Data Show Mirabegron Reduced OAB Symptoms in Men with Benign Prostatic Hyperplasia Currently Treated with Tamsulosin

- Data Presented at the American Urological Association 2019 Annual Meeting -
Apr 25, 2019

Astellas Statement on U.S. Department of Justice Settlement Related to Patient Co-Pay Assistance Foundations
Apr 3, 2019

Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
- Photos 3
Apr 1, 2019

Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy

- Study results will be presented at American Association for Cancer Research Annual Meeting 2019 -
Mar 28, 2019

Astellas: Five Consecutive Years of Perfect Equality Scores

Show per page

Statements

Careers

Stay Connected

Get only the email alerts you want.

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products